Kiniksa Pharmaceuticals reports Q1 2025 net revenue of $137.8 million for ARCALYST, forecasts 2025 revenue of $590-$605 million. Kiniksa Pharmaceuticals reported significant financial growth in Q1 ...
Earnings Call Insights: Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2025 Sanj Patel, CEO & Chairman of the Board, stated that "Year-to-date, in 2025, we've continued to execute and ...
Image source: The Motley Fool. Kiniksa Pharmaceuticals (NASDAQ:KNSA) highlighted rapid ARCALYST revenue expansion and expanding treatment adoption across its addressable pericarditis market. The ...
Detailed price information for Kiniksa Pharmaceuticals International Plc (KNSA-Q) from The Globe and Mail including charting and trades.
Kiniksa Pharmaceuticals leverages ARCALYST as it is a first-in-class FDA-approved treatment for recurrent pericarditis, driving recurring revenue and strong growth. Q3 FY2025 ARCALYST revenue was $180 ...
Hosted on MSN
Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Strong Tailwind
Kiniksa PharmaceuticalsKNSA shares currently hover just below a buy point, making the biotech stock Tuesday's choice for IBD 50 Stocks To Watch. The Lexington, Mass.-based drug maker focuses on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results